All‐cause mortality · people with fulminant hepatic failure secondary to paracetamol (acetaminophen) overdose
Intravenous acetylcysteine may leads to lower mortality compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · people with paracetamol (acetaminophen) overdose
1 finding from 1 review
Hepatotoxicity · people with paracetamol (acetaminophen) overdose
Methionine and supportive treatment may leads to lower hepatotoxicity compared with supportive treatment (low certainty).
1 finding from 1 review
Hepatotoxicity · people with paracetamol (acetaminophen) overdose
It is very uncertain whether initial infusion rate of intravenous acetylcysteine over 15 minutes changes hepatotoxicity compared with 60 minutes (very low certainty).
1 finding from 1 review
Any adverse event · people with paracetamol (acetaminophen) overdose
Initial infusion rate of intravenous acetylcysteine over 15 minutes may leads to lower any adverse event compared with 60 minutes (low certainty).
1 finding from 1 review
All‐cause mortality · people with paracetamol (acetaminophen) overdose
1 finding from 1 review
Hepatotoxicity · people with paracetamol (acetaminophen) overdose
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people with paracetamol (acetaminophen) overdose
It is very uncertain whether cysteamine changes mortality compared with dimercaprol (very low certainty).
1 finding from 1 review
Mean maximum alanine aminotransferase (IU/L) · people with paracetamol (acetaminophen) overdose
1 finding from 1 review
All‐cause mortality · people with paracetamol (acetaminophen) overdose
1 finding from 1 review
Hepatotoxicity (aspartate aminotransferase > 1000 IU/L) · people with paracetamol (acetaminophen) overdose
It is very uncertain whether cysteamine changes hepatotoxicity (aspartate aminotransferase > 1000 U/L) compared with methionine (randomised trials) (very low certainty).
1 finding from 1 review
All‐cause mortality · people with paracetamol (acetaminophen) overdose
1 finding from 1 review
All‐cause mortality · people with hepatic encephalopathy
Flumazenil showed no clear difference in all‐cause mortality compared with placebo (low certainty).
1 finding from 1 review
Hepatic encephalopathy · people with hepatic encephalopathy
Flumazenil may leads to lower hepatic encephalopathy compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · people with hepatic encephalopathy
1 finding from 1 review
All‐cause mortality · people with primary sclerosing cholangitis
It is very uncertain whether ursodeoxycholic acid changes mortality compared with placebo (very low certainty).
1 finding from 1 review
Cholecystectomy · people with primary sclerosing cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with primary sclerosing cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of people with adverse events · people with primary sclerosing cholangitis
It is very uncertain whether ursodeoxycholic acid changes proportion of people with adverse events compared with placebo (very low certainty).
1 finding from 1 review
Number of adverse events · people with primary sclerosing cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found